실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

9,268+프로그램
35+FDA 승인
4,079+모집 중
ADC 1068·Antibody 5456·CGT 2744차세대 추천 →·Data Tier →
9268프로그램35FDA 승인
0오늘 방문
568누적 방문
8122갱신 대기S–CData TierS/A/B차세대1068HER2 breast5456Antibody2744CGT→Psoriasis→NSCLC35FDA 승인
피드Data Tier차세대

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · Ebglyss혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
다음 갱신 D-13 · 마지막 7월 13일
ADCBiologicAssistance Publique - Hôpitaux …Phase 2

Adjuvant Systemic Therapy (Adjuvant Systemic Therapy)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 10%임상시험 57상태 RECRUITING
ADCBiologicEric Thompson, M.D.Phase 1

5-day TMZ (5-day TMZ)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 40%임상시험 57상태 DISCONTINUED
AntibodyPfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4
효능 ORR 100%임상시험 57상태 RECRUITING
ADCBiologicAstraZenecaDM1 in Oatp1a/b -/- was 1Phase 2

Cabazitaxel (Cabazitaxel)

Progressive Metastatic Castrate-Resistant Prostate Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 57.7%임상시험 57상태 DISCONTINUED
CGTBiologicMultan Medical And Dental Colle…Phase 2

Isotretinoin (Isotretinoin)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 95.4%임상시험 57상태 DISCONTINUED
ADCBiologicPfizerderuxtecan and tucatinibPhase 3

Tucatinib (Tucatinib)

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1)

Bone Metastases; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 57상태 ACTIVE
AntibodySanofiApproved

Dupilumab SAR231893 (Dupilumab SAR231893)

Chronic Obstructive Pulmonary Disease · Dermatitis Atopic

#DermatitisAtopic#Antibody#Approved#인기#항체+5
효능 ORR 0.44%임상시험 57상태 ACTIVE
ADCBiologicSeagenvedotin-containing regimen …Phase 2

BV (BrentuximabVedotin, BrentuximabVedotin (BV))

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 2%임상시험 56상태 ACTIVE
AntibodyIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
ADCBiologicBeijing InnoCare Pharma Tech Co…Phase 3

Orelabrutinib (Orelabrutinib)

Primary Central Nervous System Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase3#인기#항체약물접합체+3
임상시험 56상태 RECRUITING
CGTBiologicBristol-Myers SquibbPreclinical

Daclatasvir-Sofosbuvir (Daclatasvir-Sofosbuvir)

Chronic Hepatitis C (Disorder) · Chronic Hepatitis C

#ChronicHepatitisC#CGT#Preclinical#인기#세포유전치료+4
효능 ORR 97%임상시험 56상태 ACTIVE
AntibodyAbbVieApproved

adalimumab (Humira, Adalimumab treatment arm)

Psoriasis; Cardiovascular Diseases · Psoriasis

#Psoriasis#Antibody#Approved#인기#항체+5
효능 ORR 2%임상시험 56상태 ACTIVE
CGTBiologicImmunityBio, Inc.Phase 2

ALT-803 (ALT-803)

Melanoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#인기#세포유전치료+5
효능 ORR 33%임상시험 56상태 DISCONTINUED
ADCBiologicRochesPhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 69.7%임상시험 56상태 ACTIVE
ADCBiologicRemeGen Co., Ltd.sPhase 2

disitamab vedotin (Disitamab Vedotin, RC48)

Non-Muscle Invasive Bladder Cancer; HER2 · Gastric Cancer/Gastroesophageal Junction

#GastricCancerGastroesophagealJun#ADC#Phase2#인기#항체약물접합체+5
임상시험 56상태 RECRUITING
CGTBiologicMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#인기#세포유전치료+5
효능 ORR 97.1%임상시험 56상태 RECRUITING
CGTBiologicMarzieh EbrahimiPhase 1

Allogenic NK cells infusion (Allogenic NK cells infusion)

Neuroblastoma, Recurrent, Refractory; Neuroblastoma (NB) · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 5%임상시험 56상태 RECRUITING
ADCBiologicEpizyme, Inc.Phase 2

Abiraterone + prednisone (Abiraterone + prednisone)

Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer · mCRPC

#mCRPC#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 46%임상시험 56상태 RECRUITING
CGTBiologicAllife Medical Science and Tech…Phase 3

Cytokine-induced killer cells (Cytokine-induced killer cells)

Cholangiocarcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#CGT#Phase3#인기#세포유전치료+4
효능 30%임상시험 56상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 56상태 RECRUITING
CGTBiologicJiangsu Topcel-KH Pharmaceutica…Phase 2

CD19 CAR T Arm (CD19 CAR T Arm)

Scleroderma, Systemic · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 16.7%임상시험 56상태 RECRUITING
CGTBiologicCarbiogene Therapeutics Co. Ltd.Phase 1

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 55상태 ACTIVE
ADCBiologicFortis Therapeutics, Inc.Phase 2

FOR46 (FOR46)

Multiple Myeloma; Multiple Myeloma in Relapse · Prostate Cancer Metastatic

#ProstateCancerMetastatic#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 51.5%임상시험 55상태 RECRUITING
AntibodyJanssenApproved

Guselkumab (Guselkumab)

Psoriasis; Atopic Dermatitis · Skin Inflammation

#SkinInflammation#Antibody#Approved#인기#항체+5
임상시험 55상태 RECRUITING

15 / 167 페이지

← 이전다음 →
전체 9,268개 프로그램 보기